Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Dyslipidemia Pipeline Drugs Market Overview
Dyslipidemia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.
Key Targets in the Dyslipidemia Pipeline Drugs Market
The key targets in the Dyslipidemia pipeline drugs market are 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Proprotein Convertase Subtilisin/Kexin Type 9, Type 1 Angiotensin II Receptor, Apolipoprotein C III, Peroxisome Proliferator Activated Receptor Alpha, Voltage Dependent L Type Calcium Channel, and Angiopoietin Related Protein 3, Niemann Pick C1 Like Protein 1, Cannabinoid Receptor 1, and Thyroid Hormone Receptor Beta. 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase has the highest number of pipeline products.
Dyslipidemia Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Dyslipidemia Pipeline Market
The types of key MoA in the Dyslipidemia pipeline market are 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Type 1 Angiotensin II Receptor Antagonist, Apolipoprotein C III Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Voltage Dependent L Type Calcium Channel Blocker, and Angiopoietin Related Protein 3 Inhibitor. 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor has the highest number of pipeline products.
Dyslipidemia Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Dyslipidemia Pipeline Market
The key routes of administration in the Dyslipidemia pipeline market are oral, subcutaneous, intravenous, parenteral, and transdermal. Oral has the highest number of pipeline products.
Dyslipidemia Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Dyslipidemia Pipeline Drugs Market
The key molecule types in the Dyslipidemia pipeline drugs market are small molecule, monoclonal antibody, antisense RNAi oligonucleotide, antisense oligonucleotide, biologic, synthetic peptide, gene therapy, recombinant protein, cell therapy, and oligonucleotide. Small molecule has the maximum number of pipeline products.
Dyslipidemia Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Dyslipidemia Pipeline Market
The key companies in the Dyslipidemia pipeline market are Addpharma Inc, Kuhnil Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Korea United Pharm Inc, Novartis AG, Zydus Lifesciences Ltd, Boryung Pharmaceutical Co Ltd, and Celltrion Inc. Addpharma Inc has the highest number of pipeline products.
Dyslipidemia Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Proprotein Convertase Subtilisin/Kexin Type 9, Type 1 Angiotensin II Receptor, Apolipoprotein C III, Peroxisome Proliferator Activated Receptor Alpha, Voltage Dependent L Type Calcium Channel, Angiopoietin Related Protein 3, Niemann Pick C1 Like Protein 1, Cannabinoid Receptor 1, and Thyroid Hormone Receptor Beta |
| Key MoA | 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Type 1 Angiotensin II Receptor Antagonist, Apolipoprotein C III Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Voltage Dependent L Type Calcium Channel Blocker, and Angiopoietin Related Protein 3 Inhibitor |
| Key RoA | Oral, Subcutaneous, Intravenous, Parenteral, and Transdermal |
| Key molecule types | Small Molecule, Monoclonal Antibody, Antisense RNAi Oligonucleotide, Antisense Oligonucleotide, Biologic, Synthetic Peptide, Gene Therapy, Recombinant Protein, Cell Therapy, And Oligonucleotide |
| Key companies | Addpharma Inc, Kuhnil Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Korea United Pharm Inc, Novartis AG, Zydus Lifesciences Ltd, Boryung Pharmaceutical Co Ltd, and Celltrion Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
ABIONYX Pharma SA
Addpharma Inc
Afimmune Biopharma Ltd
Akcea Therapeutics Inc
Akeso Inc
Amarin Corp Plc
Arrakis Therapeutics Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
AVVA Pharmaceuticals AG
Beijing Mabworks Biotech Co Ltd
Bio-Thera Solutions Ltd
BioRestorative Therapies Inc
Boryung Pharmaceutical Co Ltd
Cardax Inc
Celltrion Inc
Centaurus Therapeutics Inc
Centeer BioTherapeutics Ltd Co
Chong Kun Dang Pharmaceutical Corp
CMG Pharmaceutical Co Ltd
Corvidia Therapeutics Inc
CVI Pharmaceuticals US Inc
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Delivra Corp
Dicerna Pharmaceuticals Inc
DongKoo Bio & Pharma Co Ltd
Eccogene (Shanghai) Co Ltd
Eli Lilly and Co
Esperion Therapeutics Inc
Genu Pharma Co Ltd
Gilead Sciences Inc
Golden Biotechnology Corp
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Halo Therapeutics Ltd
Handok Inc
Hanmi Pharmaceuticals Co Ltd
HK inno.N Corp
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
Inovio Pharmaceuticals Inc
Inversago Pharma Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Jenrin Discovery Inc
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Korea United Pharm Inc
Kotobuki Pharmaceutical Co Ltd
Kowa Co Ltd
Kuhnil Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Kyttaro Ltd
Kyung Dong Co Ltd
Les Laboratoires Servier SAS
Liid Pharmaceuticals Inc
LipimetiX Development Inc
Lyndra Therapeutics Inc.
Madrigal Pharmaceuticals Inc
Matinas BioPharma Holdings Inc
MD Healthcare Inc
Mochida Pharmaceutical Co Ltd
Navipharm Co Ltd
NewAmsterdam Pharma BV
Nippon Chemiphar Co Ltd
Nissan Chemical Corp
NorthSea Therapeutics BV
NovalGen Ltd
Novartis AG
Nubiyota LLC
NuSirt Biopharma Inc
Omeros Corp
Orient Pharma Co Ltd
Pharmena SA
Regeneron Pharmaceuticals Inc
Rivus Pharmaceuticals Inc
Saliogen Therapeutics Inc
Sequor Pharmaceuticals LLC
Shanghai Junshi Bioscience Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Sirnaomics Ltd
SJT Molecular Research SL
Staten Biotechnology BV
Suzhou Ribo Life Sciences Co Ltd
Sveikatal Inc
Synokem Pharmaceuticals Ltd
Tetranov International Inc
Torrent Pharmaceuticals Ltd
Viking Therapeutics Inc
Yooyoung Pharm Co Ltd
Yungjin Pharm Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Dyslipidemia pipeline market?
The key targets in the Dyslipidemia pipeline market are 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Proprotein Convertase Subtilisin/Kexin Type 9, Type 1 Angiotensin II Receptor, Apolipoprotein C III, Peroxisome Proliferator Activated Receptor Alpha, Voltage Dependent L Type Calcium Channel, Angiopoietin Related Protein 3, Niemann Pick C1 Like Protein 1, Cannabinoid Receptor 1, and Thyroid Hormone Receptor Beta.
-
What are the types of key MoA in the Dyslipidemia pipeline market?
The key mechanisms of action in the Dyslipidemia pipeline market are 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Type 1 Angiotensin II Receptor Antagonist, Apolipoprotein C III Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Voltage Dependent L Type Calcium Channel Blocker, and Angiopoietin Related Protein 3 Inhibitor.
-
What are the types of key RoA in the Dyslipidemia pipeline market?
The types of key RoA in the Dyslipidemia pipeline market are oral, subcutaneous, intravenous, parenteral, and transdermal.
-
What are the key molecule types in the Dyslipidemia pipeline market?
The key molecule types in the Dyslipidemia pipeline market are small molecule, monoclonal antibody, antisense RNAi oligonucleotide, antisense oligonucleotide, biologic, synthetic peptide, gene therapy, recombinant protein, cell therapy, and oligonucleotide.
-
What are the key companies in the Dyslipidemia pipeline market?
The key companies in the Dyslipidemia pipeline market are Addpharma Inc, Kuhnil Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Korea United Pharm Inc, Novartis AG, Zydus Lifesciences Ltd, Boryung Pharmaceutical Co Ltd, and Celltrion Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Metabolic Disorders reports